Leerink Partners has upgraded Eli Lilly and Co (LLY) to Outperform from Market Perform as of November 9, 2025. The stock is currently priced at $988.62.
This upgrade reflects a more favorable outlook on the company's prospects, possibly indicating improved fundamentals or stronger business performance. Eli Lilly, headquartered in Indianapolis, Indiana, operates in the pharmaceuticals industry and employs approximately 47,000 full-time employees. The company specializes in the discovery, development, manufacture, and sale of a range of pharmaceutical products, including those for cardiometabolic health, oncology, immunology, and neuroscience.
Eli Lilly's market capitalization stands at $886.2 billion, with a trailing twelve-month price-to-earnings ratio of 48.13 and earnings per share of 20.45. The company also offers a dividend yield of 64.0%.
Upcoming earnings reports are scheduled for April 28, 2026, with an estimated EPS of $7.07 and revenue of $17.2 billion, and August 4, 2026, with an estimated EPS of $7.70 and revenue of $17.9 billion.
The recent analyst consensus indicates 9 Strong Buy, 18 Buy, and 9 Hold ratings, with no Sell or Strong Sell recommendations, reflecting a general Buy consensus among the 36 analysts covering the stock.
This update provides insight into the shifting analyst sentiment surrounding Eli Lilly, which may be influenced by recent earnings performance, including a Q3 2025 EPS of $7.02, exceeding estimates by 22.0%.